Your browser is no longer supported. Please, upgrade your browser.
Settings
CARA Cara Therapeutics, Inc. daily Stock Chart
CARA [NASD]
Cara Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.10 Insider Own2.90% Shs Outstand38.88M Perf Week1.73%
Market Cap1.01B Forward P/E- EPS next Y-2.22 Insider Trans-12.44% Shs Float35.06M Perf Month27.58%
Income-79.20M PEG- EPS next Q-0.61 Inst Own57.50% Short Float18.19% Perf Quarter46.10%
Sales17.90M P/S56.17 EPS this Y-99.70% Inst Trans0.76% Short Ratio7.75 Perf Half Y68.47%
Book/sh2.90 P/B8.92 EPS next Y6.40% ROA-44.40% Target Price31.60 Perf Year34.27%
Cash/sh3.46 P/C7.48 EPS next 5Y- ROE-67.30% 52W Range12.19 - 27.55 Perf YTD98.92%
Dividend- P/FCF- EPS past 5Y-22.60% ROI-57.60% 52W High-6.13% Beta2.20
Dividend %- Quick Ratio3.40 Sales past 5Y2.40% Gross Margin- 52W Low112.14% ATR1.14
Employees55 Current Ratio3.40 Sales Q/Q- Oper. Margin- RSI (14)69.29 Volatility6.39% 4.93%
OptionableYes Debt/Eq0.00 EPS Q/Q-8.20% Profit Margin- Rel Volume1.30 Prev Close25.86
ShortableYes LT Debt/Eq0.00 EarningsAug 06 AMC Payout- Avg Volume823.16K Price25.86
Recom1.70 SMA2012.67% SMA5023.68% SMA20040.41% Volume0 Change0.00%
May-29-19Reiterated Laidlaw Buy $26 → $32
Feb-06-19Resumed Jefferies Buy $22
Jan-15-19Initiated BofA/Merrill Neutral $19
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-13-18Initiated Jefferies Buy $30
Aug-08-18Reiterated Stifel Buy $22 → $26
Jun-28-18Reiterated H.C. Wainwright Buy $24 → $26
Mar-12-18Resumed H.C. Wainwright Buy $22
Feb-12-18Upgrade Janney Neutral → Buy
Jan-19-18Initiated Seaport Global Securities Buy $27
Jun-30-17Reiterated Stifel Buy $24 → $20
Jun-30-17Reiterated Laidlaw Buy $35 → $30
Jun-30-17Downgrade Janney Buy → Neutral
Mar-28-17Reiterated Laidlaw Buy $20 → $35
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Mar-10-17Reiterated Laidlaw Buy $17 → $20
Oct-13-16Initiated H.C. Wainwright Buy $20
Aug-08-16Reiterated Needham Buy $27 → $23
Feb-29-16Reiterated Laidlaw Buy $30 → $17
Nov-04-15Initiated Cantor Fitzgerald Buy
Jul-22-19 07:00AM  Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVA in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment GlobeNewswire
Jul-17-19 07:15PM  Cara Therapeutics Inc (CARA) CFO & Chief Strategy Officer Mani Mohindru Sold $935,775 of Shares GuruFocus.com
Jul-16-19 10:28AM  4 Strong Buy Biotechs With Big 3Q19 Catalysts TipRanks
Jul-14-19 07:30AM  3 Top Biotech Stocks to Buy for the 2nd Half of 2019 Motley Fool
Jul-13-19 07:56AM  Estimating The Fair Value Of Cara Therapeutics, Inc. (NASDAQ:CARA) Simply Wall St.
Jul-12-19 06:27PM  GuruFocus Value Idea Contest Sees 2 Winners! GuruFocus.com +6.91%
Jul-11-19 08:30AM  Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA for Pruritus in Patients with Atopic Dermatitis PR Newswire
Jul-09-19 07:00AM  Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis GlobeNewswire
Jul-02-19 07:16AM  Better Buy: GW Pharmaceuticals vs. Cara Therapeutics Motley Fool
Jun-26-19 07:00AM  Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC) GlobeNewswire
12:54AM  Top Marijuana Stocks on the NASDAQ Investopedia
Jun-13-19 07:04PM  Understanding Medical Cannabis vs. Recreational Cannabis Stocks Investopedia
Jun-02-19 09:09AM  Is Cara Therapeutics a Buy Now? Motley Fool
Jun-01-19 10:17AM  Cara Therapeutics surges 15.7% after company announces positive late-stage data for itchiness treatment MarketWatch
May-31-19 07:00AM  Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-30-19 07:48AM  Cara Shares Up on Positive Phase III Data for Itchiness Drug Zacks
May-29-19 02:30PM  Cara Therapeutics Surges on Phase 3 Results for Itchiness Treatment TheStreet.com +19.97%
01:13PM  Stocks making the biggest moves midday: Canada Goose, Capri Holdings, General Mills & more CNBC
11:48AM  Cara Therapeutics Rallies On Positive Clinical Readout For Pruritis Drug Benzinga
11:36AM  Why Cara Therapeutics Stock Is Soaring Today Motley Fool
09:36AM  Announcing: Cara Therapeutics (NASDAQ:CARA) Stock Increased An Energizing 193% In The Last Three Years Simply Wall St.
09:02AM  Cara Therapeutics stock up 12.6% after company announces positive Phase 3 data for itchiness treatment MarketWatch
07:00AM  Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA Injection in Hemodialysis Patients with Pruritus GlobeNewswire
06:00AM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
May-28-19 10:43AM  3 Strong Buy Cannabis Biotech Stocks To Know Now TipRanks
May-23-19 08:09AM  Edited Transcript of CARA earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
07:10AM  Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use InvestorPlace
May-17-19 06:00AM  3 Small-Cap Biotech Stocks You Can Buy Right Now Motley Fool
May-09-19 01:12PM  Did Hedge Funds Drop The Ball On Casa Therapeutics Inc (CARA) ? Insider Monkey
May-08-19 04:01PM  Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference GlobeNewswire
02:23PM  Cara Therapeutics Inc (CARA) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 06:25PM  Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates Zacks -5.71%
05:15PM  Cara: 1Q Earnings Snapshot Associated Press
04:01PM  Cara Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire
May-06-19 08:52AM  Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options Zacks
Apr-30-19 04:01PM  Cara Therapeutics to Announce First Quarter 2019 Financial Results on May 7, 2019 GlobeNewswire
Apr-29-19 09:30AM  Are There Cannabis Stocks in Your Portfolio? Heres the Straight Dope ETF Trends
Apr-16-19 08:30AM  CBD Company to Research Now ACCESSWIRE
Apr-14-19 02:00PM  Better Buy: GW Pharmaceuticals vs. Cara Therapeutics Motley Fool
Apr-11-19 07:50AM  Cara Therapeutics Posts 2018 Revenue 15X over 2017, Questions, Catalysts, and Hurdles Every Marijuana Stock Investor Should be Considering ACCESSWIRE
Apr-09-19 08:40AM  Why Cara Therapeutics Stock Jumped 15.1% in March Motley Fool
Apr-08-19 10:00AM  3 Top Biotech Stocks to Buy in April Motley Fool
Apr-07-19 02:00PM  3 Top Small-Cap Biotech Stocks for Aggressive Investors Motley Fool
Apr-03-19 02:48PM  Edited Transcript of CARA earnings conference call or presentation 12-Mar-19 8:30pm GMT Thomson Reuters StreetEvents
Apr-02-19 04:01PM  Cara Therapeutics to Present at the 18th Annual Needham Healthcare Conference GlobeNewswire
Mar-29-19 07:20AM  Analysis: Positioning to Benefit within American Water Works, TripAdvisor, ACADIA Pharmaceuticals, Dril-Quip, Domtar, and Cara Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-22-19 01:00PM  Cannabis Breakout Candidates - THC Therapeutics, Inc. (THCT) ACCESSWIRE -6.82%
Mar-13-19 01:01PM  Here's Why Cara Therapeutics Stock Rose as Much as 13.9% Today Motley Fool +11.76%
12:15PM  These Four Marijuana Stocks Are Raising Eyebrows on Wednesday ACCESSWIRE
12:19AM  Cara Therapeutics Inc (CARA) Q4 2018 Earnings Conference Call Transcript Motley Fool
Mar-12-19 05:35PM  Stocks making the biggest moves after hours: Switch, Clearwater Paper and more CNBC
05:20PM  Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:27PM  Cara: 4Q Earnings Snapshot Associated Press
04:01PM  Cara Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
10:00AM  Top Cannabis Plays-THC Therapeutics, Inc ACCESSWIRE
Mar-07-19 08:57AM  Athersys (ATHX) Q4 Earnings: What's in Store for the Stock? Zacks
08:51AM  Is a Beat in Store for Catabasis (CATB) This Earnings Season? Zacks
Mar-05-19 04:01PM  Cara Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019 GlobeNewswire
Mar-04-19 06:41AM  Can Segmental Growth Aid Cooper Companies' (COO) Q1 Earnings? Zacks
Mar-03-19 10:15AM  Better Buy: Cara Therapeutics vs. Scotts Miracle-Gro Company Motley Fool
Feb-28-19 10:21AM  New Cannabis Products Which Could Disrupt the Industry in 2019 Investopedia
Feb-22-19 04:43PM  What's in Store for Vericel (VCEL) This Earnings Season? Zacks
Feb-15-19 08:20AM  Consolidated Research: 2019 Summary Expectations for Tenaris S.A, Rapid7, Halozyme Therapeutics, Cara Therapeutics, EnPro Industries, and K12 Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-13-19 01:47PM  Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks? InvestorPlace
Feb-12-19 09:00AM  Biotech Plays in the News You Should Know ACCESSWIRE
Feb-11-19 01:56PM  Here's Why Cara Therapeutics Stock Rose 17.3% in January Motley Fool
Feb-08-19 12:10PM  These 4 Marijuana Stocks Are Looking Strong ACCESSWIRE +10.31%
Feb-06-19 02:45PM  Watch These Marijuana Stocks Hit The Ground Running On Wednesday (2/6/19) ACCESSWIRE
Feb-05-19 08:00AM  Biotech Stocks to Watch ACCESSWIRE
Jan-31-19 04:09PM  Better Buy: GW Pharmaceuticals vs. Cara Therapeutics Motley Fool
08:30AM  Biotechs Investors Are Flocking To ACCESSWIRE
Jan-29-19 08:30AM  Cannabis and Biotech Stocks that Could Explode ACCESSWIRE
Jan-28-19 08:00AM  Biotech Stocks to Watch this Week ACCESSWIRE
Jan-24-19 12:08PM  Is Cara Therapeutics a Buy? Motley Fool
08:10AM  Consolidated Research: 2019 Summary Expectations for First Data, IDEXX Laboratories, CMS Energy, Worthington Industries, Triumph Group, and Cara Therapeutics Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-18-19 09:36AM  With Trial Results Due, This Could Be a Breakout Year for Cara Stock InvestorPlace
Jan-15-19 11:10AM  Bank Of America Takes Neutral Stance On Cara Therapeutics Ahead Of Phase 3 Korsuva Results Benzinga
Jan-10-19 09:19PM  Here's Why Cara Therapeutics Fell 28.5% in December Motley Fool
Jan-07-19 07:00AM  Cara Therapeutics Completes Enrollment of KALM-1 Pivotal Phase 3 Trial Of KORSUVA (CR845/ difelikefalin) Injection in Hemodialysis Patients with Pruritus GlobeNewswire +5.34%
Jan-04-19 05:11PM  Which Biopharma Stocks Are Looking To Score Big In Cannabis Medicine? Investor's Business Daily +5.34%
Jan-03-19 05:43PM  Cara (CARA) Up on IDMC's Recommendation to Continue Trial Zacks
Jan-02-19 07:00AM  Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim Statistical Assessment For KALM-1 Phase 3 Trial Of KORSUVA Injection in Hemodialysis Patients with Pruritus GlobeNewswire +12.00%
Dec-23-18 03:38AM  Is Casa Therapeutics Inc (CARA) Going to Burn These Hedge Funds? Insider Monkey
Dec-19-18 12:20PM  Cara Therapeutics Stock Could Outperform in 2019 InvestorPlace
Dec-18-18 08:45AM  4 Marijuana Stocks To Watch On Tuesday 12/18/2018 ACCESSWIRE
07:33AM  Jim Cramer Advises His Viewers On Apache, Waste Management And More Benzinga
Dec-17-18 06:48PM  Cramer's lightning round: 'Yield will protect you in this awful market' CNBC
09:20AM  A Solution to the Nation's Current Opioid Overdose Epidemic and The World's Leading Cause of Disability ACCESSWIRE
Dec-14-18 06:30AM  This Unknown Stock With A Market Opportunity Rivaling Cannabis Could Offer Big Upside For Investors ACCESSWIRE
Dec-11-18 10:20AM  CBD Industry Growth Sparks Momentum For Marijuana Stocks ACCESSWIRE
Dec-10-18 10:35AM  Alternatives to Watch ACCESSWIRE
Dec-03-18 10:46AM  The Trade War Could Be a Positive Catalyst for Cara Therapeutics Stock InvestorPlace
Dec-02-18 09:17AM  Why Cara Therapeutics Is Up 50% in 2018 Motley Fool
Nov-21-18 11:30AM  Opioid Alternatives Could Make Investors Major Gains ACCESSWIRE
Nov-16-18 09:00AM  12 NYSE- And NASDAQ-Listed Stocks With Cannabis Exposure Benzinga
Nov-12-18 08:20AM  Research Report Identifies DXP Enterprises, Diebold Nixdorf, Fitbit, Nevro, Plains All American Pipeline, and Cara Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-10-18 09:27AM  Edited Transcript of CARA earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-08-18 04:01PM  Cara Therapeutics to Present at November Investor Conferences GlobeNewswire
Nov-06-18 06:00PM  Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:57PM  Cara: 3Q Earnings Snapshot Associated Press
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease (CKD) associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from chronic kidney disease-associated pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that is in Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; and in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DJul 17Sale27.508,996247,390119,886Jul 19 05:47 PM
Mohindru ManiCFO & Chief Strategy OfficerJul 15Option Exercise14.0637,431526,28051,294Jul 17 05:46 PM
Mohindru ManiCFO & Chief Strategy OfficerJul 15Sale25.0037,431935,77513,863Jul 17 05:46 PM
Ives Jeffrey L.DirectorJul 01Option Exercise5.322,50013,3008,500Jul 03 04:04 PM
Ives Jeffrey L.DirectorJul 01Sale21.752,50054,3756,000Jul 03 04:04 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DJul 01Sale21.9020,000438,000128,882Jul 03 03:59 PM
CHALMERS DEREK TPresident & CEOMay 29Sale21.425,528118,410958,468May 30 06:18 PM
Terrillion ScottSec'y; Chief Compliance & G.C.May 29Sale21.382,30349,23812,416May 30 06:19 PM
Mohindru ManiCFO & Chief Strategy OfficerMay 29Sale21.392,49653,38913,863May 30 06:17 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DMay 29Sale21.1911,397241,502148,882May 30 06:16 PM
Mohindru ManiCFO & Chief Strategy OfficerMar 13Option Exercise14.0616,041225,53624,067Mar 15 04:42 PM
Mohindru ManiCFO & Chief Strategy OfficerMar 13Sale19.1216,041306,7048,026Mar 15 04:42 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DMar 13Sale18.8716,803317,073122,779Mar 14 05:13 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DMar 12Sale17.503,19755,948139,582Mar 14 05:13 PM
CHALMERS DEREK TPresident & CEOMar 01Sale17.049,792166,856943,996Mar 05 04:53 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentFeb 28Sale17.501,50026,250142,779Mar 04 05:49 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentFeb 25Sale17.502,20038,500144,279Feb 27 05:29 PM
CHALMERS DEREK TPresident & CEOFeb 01Sale14.9920,000299,800953,788Feb 05 04:27 PM
CHALMERS DEREK TPresident & CEOJan 04Sale15.045,00075,200973,788Jan 04 04:22 PM
CHALMERS DEREK TPresident & CEOJan 02Sale13.1315,000196,950978,788Jan 04 04:22 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentDec 28Sale12.534,30053,879146,479Jan 02 05:56 PM
CHALMERS DEREK TPresident & CEODec 28Sale12.5315,825198,287993,788Jan 02 05:55 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Dec 28Sale12.513,10038,7816,386Jan 02 05:56 PM
Mohindru ManiCFO & Chief Strategy OfficerDec 28Sale12.554,50056,4758,026Jan 02 05:54 PM
CHALMERS DEREK TPresident & CEODec 03Sale18.1720,000363,400971,392Dec 06 04:16 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentDec 03Sale18.363,00055,080139,000Dec 06 04:18 PM
Mohindru ManiCFO & Chief Strategy OfficerNov 15Option Exercise14.0616,042225,55116,042Nov 16 04:22 PM
Mohindru ManiCFO & Chief Strategy OfficerNov 15Sale18.5016,042296,7770Nov 16 04:22 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentNov 01Option Exercise2.0540,00082,000145,000Nov 05 08:25 PM
CHALMERS DEREK TPresident & CEONov 01Sale18.7820,000375,600991,392Nov 02 05:35 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentNov 01Sale18.773,00056,310142,000Nov 05 08:25 PM
Mohindru ManiCFO & Chief Strategy OfficerOct 17Option Exercise14.0616,042225,55116,042Oct 19 04:32 PM
Stauffer Joseph WilliamChief Medical OfficerOct 17Sale20.1311,442230,3472,000Oct 19 04:34 PM
Mohindru ManiCFO & Chief Strategy OfficerOct 17Sale20.1916,042323,8880Oct 19 04:32 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentOct 01Sale23.993,00071,97095,000Oct 03 04:09 PM
CHALMERS DEREK TPresident & CEOOct 01Sale23.7920,000475,8001,011,392Oct 03 04:08 PM
CHALMERS DEREK TPresident & CEOSep 04Sale19.7120,000394,2001,031,392Sep 06 05:34 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentSep 04Sale19.813,00059,43098,000Sep 06 05:33 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentAug 20Sale18.893,00056,670101,000Aug 22 05:26 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentAug 06Option Exercise2.2510,00022,500114,000Nov 05 08:21 PM